Retrospective study of radiotherapy-induced skin reactions in breast cancer patients: Reduced incidence of moist desquamation with a hydroactive colloid gel versus dexpanthenol

2014 ◽  
Vol 18 (5) ◽  
pp. 499-504 ◽  
Author(s):  
Sandrine Censabella ◽  
Stefan Claes ◽  
Marc Orlandini ◽  
Roel Braekers ◽  
Herbert Thijs ◽  
...  
2007 ◽  
Vol 69 (3) ◽  
pp. 685-693 ◽  
Author(s):  
Tomo Suga ◽  
Atsuko Ishikawa ◽  
Masakazu Kohda ◽  
Yoshimi Otsuka ◽  
Shigeru Yamada ◽  
...  

Oncotarget ◽  
2017 ◽  
Vol 8 (44) ◽  
pp. 75864-75873 ◽  
Author(s):  
Qiao Li ◽  
Zhao Yang ◽  
Jinhu Fan ◽  
Jianjun He ◽  
Bin Zhang ◽  
...  

2018 ◽  
Vol 17 (4) ◽  
pp. 417-421
Author(s):  
Omid Baziar ◽  
Hamid Gholamhosseinian ◽  
Mohammad Naser Forghani

AbstractPurposeTo assess skin dose and incidence of skin reactions in early breast cancer patients treated via Intrabeam™ intraoperative radiation therapy (IORT) device.Materials and methodsIn total, 250 breast cancer patients treated with a single fraction of 20 Gy using 50 kV photon were recruited. The applicator to skin distance (ASD) was measured before the initiation of the radiation and the skin dose in each patient was accordingly calculated based on the treatment planning system (TPS).ResultsThe average skin doses calculated were equal to 7·91, 5·83, 3·96 and 2·14 Gy for 6–10, 10–15, 15–20 and 20–30 mm ASD values, respectively. It is noticeable that the skin doses could be lower than the TPS measurements up to 45%, mostly due to lack of backscatter radiation in breast tissue compared with the full scatter condition in the Zeiss water phantom. Finally, only three patients showed low-grade skin reactions 1 week after IORT. A review of the related literature also revealed the incidence of lower skin complications among patients treated via Intrabeam™ compared with MammoSite™ machine.ConclusionsThe Intrabeam™ TPS did not seem to be very reliable for accurate skin dosimetry. However, breast cancer treatment using Intrabeam™ could result in fewer incidences of skin reactions than MammoSite™ machine.


2019 ◽  
Vol 19 (4) ◽  
pp. 365-369 ◽  
Author(s):  
Leona McAlinden ◽  
Andrea Mullan ◽  
Paul Shepherd

AbstractAim:Breast cancer patients experience skin reactions during radiotherapy. Radiation-induced skin reactions can result in treatment delivery being interrupted. The aim of this paper is to evaluate the skincare management of patients receiving radiotherapy for breast cancer in order to inform best practice.Method:A literature search was undertaken using USearch and HONNI in support of the first-hand evidence gained from the supervised on-treatment review of patients receiving radiotherapy for breast cancer.Results:There is evidence to suggest that the skincare advice given to patients varies widely between departments in the UK with many not following nationally recommended guidelines. Studies demonstrate that there are ways to reduce skin reactions and that there are a range of effective management strategies being adopted. Prophylactic skincare has been explored to improve the resilience of the skin prior to commencing radiotherapy.Findings:Further investigation is required in order to clearly establish the optimum national skincare management for breast cancer patients. More studies are required to test the effectiveness and viability of prophylactic measures. Skincare guidance needs to be robustly developed and effectively promoted by therapeutic radiographers for radiotherapy patients to benefit from reduced, radiation-induced, skin reactions.


2012 ◽  
Vol 30 (3) ◽  
pp. 253-264 ◽  
Author(s):  
David K. Wellisch ◽  
Sarah R. Ormseth ◽  
Narineh Hartoonian ◽  
Jason E. Owen

Sign in / Sign up

Export Citation Format

Share Document